About Larimar Therapeutics, Inc. Common Stock
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Market Cap
$0.14B
Employees
42
Listed Since
May 29, 2020
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.larimartx.comPhone
844-511-9056
Headquarters
THREE BALA PLAZA EAST. SUITE 506
BALA CYNWYD, PA 19004
CIK
0001374690